Last reviewed · How we verify
Sclersing liqiud of Lauromacrogol
Sclersing liqiud of Lauromacrogol is a Small molecule drug developed by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine. It is currently FDA-approved.
At a glance
| Generic name | Sclersing liqiud of Lauromacrogol |
|---|---|
| Sponsor | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Multicenter Prospective Clinical Study of Endoscopic Foam Sclerotherapy for Internal Hemorrhoids (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sclersing liqiud of Lauromacrogol CI brief — competitive landscape report
- Sclersing liqiud of Lauromacrogol updates RSS · CI watch RSS
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine portfolio CI
Frequently asked questions about Sclersing liqiud of Lauromacrogol
What is Sclersing liqiud of Lauromacrogol?
Sclersing liqiud of Lauromacrogol is a Small molecule drug developed by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine.
Who makes Sclersing liqiud of Lauromacrogol?
Sclersing liqiud of Lauromacrogol is developed and marketed by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine (see full Xinhua Hospital, Shanghai Jiao Tong University School of Medicine pipeline at /company/xinhua-hospital-shanghai-jiao-tong-university-school-of-medicine).
What development phase is Sclersing liqiud of Lauromacrogol in?
Sclersing liqiud of Lauromacrogol is FDA-approved (marketed).